Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Study to Assess the Safety and Tolerability of DDY391 in Adult Participants With Active Moderate to Severe Psoriatic Arthritis Who Have Completed Study Treatment in CDDY391A12201

NCT07923773 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT07923773 Not yet recruiting Phase 2 88 participants (estimated) Started 2027

Follow this trial by email Email me the PDF

Get the NCT07923773 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started February 2027. Interventional study, Phase 2, 88 participants (estimated). Lead sponsor Novartis Pharmaceuticals. Primary measure: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs).

How it compares

59 similar trials: same condition (Arthritis, Psoriatic) and phase

Enrollment

This trial
88
Middle half
45 to 206
Median
146
Trials with a value
59

Months from start to completion

This trial
35
Middle half
16.8 to 35.2
Median
25.3
Trials with a value
58

Sites

This trial
Not reported
Middle half
1 to 41
Median
22
Trials with a value
53
Posted results or a linked paper 61% 36 of 59 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Study to Assess the Safety and Tolerability of DDY391 in Adult Participants With Active Moderate to Severe Psoriatic Arthritis Who Have Completed Study Treatment in CDDY391A12201
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 10, 2027
Completion date
January 11, 2030
Enrollment
88 (estimated)
Sites
Not reported

Conditions

MeSH condition names; the registry's own terms follow.

Arthritis, Psoriatic

Registry terms: moderate to severe psoriatic arthritis

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Maximum age
100 Years
Healthy volunteers
No
Study type
Interventional
Lead sponsor
Novartis Pharmaceuticals

Arms

As registered; 1 arm.

Registered arms
Arm Type Interventions
DDY391 Experimental DDY391
Show registry wording

Participants will receive DDY391

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) Up to 56 Weeks
Show registry wording

Number of participants with AEs and SAEs, including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs.

Lead sponsor's other trials

Novartis Pharmaceuticals, most recent start first.

Similar trials

Same condition (Arthritis, Psoriatic) and phase, most recent start first.